Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12889719rdf:typepubmed:Citationlld:pubmed
pubmed-article:12889719lifeskim:mentionsumls-concept:C0040845lld:lifeskim
pubmed-article:12889719lifeskim:mentionsumls-concept:C0441723lld:lifeskim
pubmed-article:12889719lifeskim:mentionsumls-concept:C0165631lld:lifeskim
pubmed-article:12889719lifeskim:mentionsumls-concept:C0288792lld:lifeskim
pubmed-article:12889719lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:12889719lifeskim:mentionsumls-concept:C0017243lld:lifeskim
pubmed-article:12889719lifeskim:mentionsumls-concept:C0037633lld:lifeskim
pubmed-article:12889719lifeskim:mentionsumls-concept:C0524527lld:lifeskim
pubmed-article:12889719lifeskim:mentionsumls-concept:C1382100lld:lifeskim
pubmed-article:12889719lifeskim:mentionsumls-concept:C1511559lld:lifeskim
pubmed-article:12889719pubmed:issue1lld:pubmed
pubmed-article:12889719pubmed:dateCreated2003-7-31lld:pubmed
pubmed-article:12889719pubmed:abstractTextForty-two subjects with normal skin were enrolled in a single-center study to assess the cumulative irritancy potential of adapalene (Differin gel 0.1% and Differin solution 0.1%) compared with tazarotene (Tazorac gels 0.05% and 0.1%), tretinoin (Retin-A Micro gel 0.1%, Avita cream 0.025%, and Avita gel 0.025%), and white petrolatum (negative control). All test materials were applied randomly, under occlusion, to sites located on either side of the midline--the mid thoracic area of the subjects' backs. All patches were applied daily, Monday through Friday, to the same sites, unless the degree of reaction to a test product or adhesive necessitated removal (grade 3). Thirty-eight of the 42 subjects (90.5%) completed the study. Thirty-four of those 38 subjects (89.5%) had to discontinue using both tazarotene concentrations due to intolerance. Patch discontinuations for the remaining test materials were as follows: 7 subjects discontinued use of tretinoin microsphere gel 0.1%, 3 discontinued tretinoin cream 0.025%, 1 discontinued tretinoin gel 0.025%, and 1 discontinued adapalene gel 0.1%. None of the subjects discontinued use of the white petrolatum or the adapalene solution 0.1%. Adapalene gel and solution 0.1% were statistically (P<.01) less irritating than both tazarotene gels 0.1% and 0.05%, tretinoin microsphere gel 0.1%, and tretinoin gel 0.025%, and they were not statistically different from tretinoin gel 0.025%.lld:pubmed
pubmed-article:12889719pubmed:languageenglld:pubmed
pubmed-article:12889719pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12889719pubmed:citationSubsetIMlld:pubmed
pubmed-article:12889719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12889719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12889719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12889719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12889719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12889719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12889719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12889719pubmed:statusMEDLINElld:pubmed
pubmed-article:12889719pubmed:monthJullld:pubmed
pubmed-article:12889719pubmed:issn0011-4162lld:pubmed
pubmed-article:12889719pubmed:authorpubmed-author:GilbertRichar...lld:pubmed
pubmed-article:12889719pubmed:authorpubmed-author:GreenspanAlan...lld:pubmed
pubmed-article:12889719pubmed:authorpubmed-author:PoncetMichelMlld:pubmed
pubmed-article:12889719pubmed:authorpubmed-author:BakerMichael...lld:pubmed
pubmed-article:12889719pubmed:authorpubmed-author:LoescheChrist...lld:pubmed
pubmed-article:12889719pubmed:authorpubmed-author:VendettiNancy...lld:pubmed
pubmed-article:12889719pubmed:authorpubmed-author:GeorgeianKath...lld:pubmed
pubmed-article:12889719pubmed:authorpubmed-author:SotoPascalePlld:pubmed
pubmed-article:12889719pubmed:issnTypePrintlld:pubmed
pubmed-article:12889719pubmed:volume72lld:pubmed
pubmed-article:12889719pubmed:ownerNLMlld:pubmed
pubmed-article:12889719pubmed:authorsCompleteYlld:pubmed
pubmed-article:12889719pubmed:pagination76-81lld:pubmed
pubmed-article:12889719pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:meshHeadingpubmed-meshheading:12889719...lld:pubmed
pubmed-article:12889719pubmed:year2003lld:pubmed
pubmed-article:12889719pubmed:articleTitleCumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations.lld:pubmed
pubmed-article:12889719pubmed:affiliationTKL Research, Inc, Paramus, New Jersey, USA.lld:pubmed
pubmed-article:12889719pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12889719pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12889719pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12889719pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:12889719pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed